Cargando…

Bioorthogonal Catalytic Activation of Platinum and Ruthenium Anticancer Complexes by FAD and Flavoproteins

Recent advances in bioorthogonal catalysis promise to deliver new chemical tools for performing chemoselective transformations in complex biological environments. Herein, we report how FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), and four flavoproteins act as unconventional photoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso‐de Castro, Silvia, Cortajarena, Aitziber L., López‐Gallego, Fernando, Salassa, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887934/
https://www.ncbi.nlm.nih.gov/pubmed/29359850
http://dx.doi.org/10.1002/anie.201800288
Descripción
Sumario:Recent advances in bioorthogonal catalysis promise to deliver new chemical tools for performing chemoselective transformations in complex biological environments. Herein, we report how FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), and four flavoproteins act as unconventional photocatalysts capable of converting Pt(IV) and Ru(II) complexes into potentially toxic Pt(II) or Ru(II)−OH(2) species. In the presence of electron donors and low doses of visible light, the flavoproteins mini singlet oxygen generator (miniSOG) and NADH oxidase (NOX) catalytically activate Pt(IV) prodrugs with bioorthogonal selectivity. In the presence of NADH, NOX catalyzes Pt(IV) activation in the dark as well, indicating for the first time that flavoenzymes may contribute to initiating the activity of Pt(IV) chemotherapeutic agents.